La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company company information, Employees & Contact Information

La Jolla Pharmaceutical Company, a subsidiary of Innoviva, Inc., is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla markets GIAPREZA® (angiotensin II) injection and XERAVA® (eravacycline) for injection. For more information, please visit www.ljpc.com.

Company Details

Employees
95
Founded
-
Address
201 Jones Rd, Suite 400, Waltham,ma 02451,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
ljpc.com
HQ
Waltham, MA
Looking for a particular La Jolla Pharmaceutical Company employee's phone or email?

La Jolla Pharmaceutical Company Questions

News

La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results - GlobeNewswire

La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results GlobeNewswire

Innoviva to Acquire La Jolla Pharmaceutical Company - Business Wire

Innoviva to Acquire La Jolla Pharmaceutical Company Business Wire

Innoviva to Acquire La Jolla Pharmaceutical Company - citybiz

Innoviva to Acquire La Jolla Pharmaceutical Company citybiz

La Jolla Pharmaceutical (LJPC) Stock Skyrockets on Innoviva Acquisition News - InvestorPlace

La Jolla Pharmaceutical (LJPC) Stock Skyrockets on Innoviva Acquisition News InvestorPlace

La Jolla Pharmaceutical Posts Top-Line Results from Phase 3 Study of LJPC-501 - drugdiscoverytrends.com

La Jolla Pharmaceutical Posts Top-Line Results from Phase 3 Study of LJPC-501 drugdiscoverytrends.com

La Jolla Pharmaceutical Company Announces Management Transition - GlobeNewswire

La Jolla Pharmaceutical Company Announces Management Transition GlobeNewswire

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Corporate Progress - Business Wire

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Corporate Progress Business Wire

La Jolla Pharmaceutical Company Announces Positive Results - GlobeNewswire

La Jolla Pharmaceutical Company Announces Positive Results GlobeNewswire

La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe - Business Wire

La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe Business Wire

Innoviva Completes Acquisition of La Jolla Pharmaceutical - Business Wire

Innoviva Completes Acquisition of La Jolla Pharmaceutical Business Wire

La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc. - GlobeNewswire

La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc. GlobeNewswire

Top La Jolla Pharmaceutical Company Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant